Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.75 |
| ▸ | RAB9A | P51151 | 2/20 | 0.75 |
| ▸ | MMP13 | P45452 | 1/20 | 0.69 |
| ▸ | HPGD | P15428 | 2/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.63 |
| ▸ | CA1 | P00915 | 2/20 | 0.62 |
| ▸ | CA2 | P00918 | 2/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.61 |
| ▸ | PKM | P14618 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | POLB | P06746 | 2/20 | 0.60 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.60 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.60 |
| ▸ | RELA | Q04206 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | PLK1 | P53350 | 1/20 | 0.59 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16685001 | 0.91 | NPC1 (0.83) | NPC1RAB9AHPGDSMN1; SMN2CA1 | |
| SCHEMBL4693371 | 0.88 | ALDH1A1 (0.70) | NPC1RAB9AMMP13HPGDSMN1; SMN2 | |
| SCHEMBL11761105 | 0.86 | NPC1 (1.00) | NPC1RAB9AHPGDSMN1; SMN2CA1 | |
| SCHEMBL14271589 | 0.86 | NPC1 (0.75) | NPC1RAB9AHPGDSMN1; SMN2CA1 | |
| SCHEMBL11759659 | 0.86 | NPC1 (1.00) | NPC1RAB9AHPGDSMN1; SMN2CA1 | |
| SCHEMBL11758269 | 0.86 | NPC1 (1.00) | NPC1RAB9AHPGDSMN1; SMN2CA1 | |
| SCHEMBL11754310 | 0.86 | NPC1 (1.00) | NPC1RAB9AHPGDSMN1; SMN2CA1 | |
| SCHEMBL11755990 | 0.86 | NPC1 (1.00) | NPC1RAB9AHPGDSMN1; SMN2CA1 | |
| SCHEMBL9489987 | 0.86 | NPC1 (1.00) | NPC1RAB9AHPGDSMN1; SMN2CA1 | |
| SCHEMBL6360344 | 0.86 | NPC1 (0.75) | NPC1RAB9AHPGDSMN1; SMN2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3030554-B1 | PIPERIDINE UREA DERIVATIVES | MERCK PATENT GMBH (DE) | 2018-02-28 | — | — | EP | claimed |
| US-9770446-B2 | Piperidine urea derivatives | MERCK PATENT GMBH (DE) | 2017-09-26 | — | — | US | claimed |
| US-20160184285-A1 | PIPERIDINE UREA DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-06-30 | — | — | US | claimed |
| EP-3030554-A1 | PIPERIDINE UREA DERIVATIVES | Merck Patent GmbH (DE) | 2016-06-15 | — | — | EP | claimed |
| WO-2015018475-A1 | PIPERIDINE UREA DERIVATIVES | MERCK PATENT GMBH (DE) | 2015-02-12 | — | — | WO | claimed |
| EP-3030554-B1 | PIPERIDINE UREA DERIVATIVES | MERCK PATENT GMBH (DE) | 2018-02-28 | — | — | EP | disclosed |
| US-9770446-B2 | Piperidine urea derivatives | MERCK PATENT GMBH (DE) | 2017-09-26 | — | — | US | disclosed |
| US-20160184285-A1 | PIPERIDINE UREA DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-06-30 | — | — | US | disclosed |
| CN-105073725-A | Pyrazolyl-ureas as kinase inhibitors | RESPIVERT LTD | 2015-11-18 | — | — | CN | disclosed |
| EP-1658263-A1 | NOVEL AMINOBENZOPHENONE COMPOUNDS | Leo Pharma A/S (DK) | 2006-05-24 | — | — | EP | disclosed |
| WO-2005009940-A1 | NOVEL AMINOBENZOPHENONE COMPOUNDS | LEO PHARMA A/S (DK) | 2005-02-03 | — | — | WO | disclosed |
| US-6825338-B2 | SELECTIVE FUNCTIONALIZATION OF OLIGONUCLEOTIDES WITH CONJUGATE GROUPS WITHOUT THE NEED FOR POST-SYNTHETIC LABELING; SOLID PHASE SYNTHESIS; DEBLOCKING AN ACID LABILE HYDROXYL GROUP AND REACTING WITH A PHOSPHORAMIDITE | ISIS PHARMACEUTICALS, INC. | 2004-11-30 | — | — | US | disclosed |
| US-20040082774-A1 | Novel phosphate and thiophosphate protecting groups | ISIS PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
| EP-1379541-A1 | LABELED OLIGONUCLEOTIDES, METHODS FOR MAKING SAME, AND COMPOUNDS USEFUL THEREFOR | ISIS Pharmaceuticals, Inc. (US) | 2004-01-14 | — | — | EP | disclosed |
| US-20030208061-A1 | Labeled oligonucleotides, methods for making same, and compounds useful therefor | ISIS PHARMACEUTICALS, INC. | 2003-11-06 | — | — | US | disclosed |
| US-6610837-B1 | Preparation of an oligonucleotide compound of given formula by reacting with given compounds, followed by oxidation or sulfurization | ISIS PHARMACEUTICALS, INC. | 2003-08-26 | — | — | US | disclosed |
| WO-2002079216-A1 | LABELED OLIGONUCLEOTIDES, METHODS FOR MAKING SAME, AND COMPOUNDS USEFUL THEREFOR | ISIS PHARMACEUTICALS, INC. (US) | 2002-10-10 | — | — | WO | disclosed |
| WO-2000056332-A1 | SULTAMS: CATALYST SYSTEMS FOR ASYMMETRIC REDUCTION OF A C=N INTERMEDIATE BIOLOGICAL COMPOSITIONS AND METHODS FOR MAKING THE SULTAMS | THE UNIVERSITY OF TENNESSEE RESEARCH CORPORATION (US) | 2000-09-28 | — | — | WO | disclosed |
| US-6121437-A | SYNTHESIS OF OLIGONUCLEOTIDES USING OLIGONUCLEOTIDES OR NUCLEOTIDES WITH PROTECTED INTERNUCLEOSIDIC PHOSPHORUS FUNCTIONALITIES WHICH CAN BE REMOVED UNDER MILD CONDITIONS AND PRODUCE NONTOXIC BY-PRODUCTS | ISIS PHARMACEUTICALS, INC. (US) | 2000-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030208061-A1 | Labeled oligonucleotides, methods for making same, and compounds useful therefor | METTL16, BCDIN3D, GARS1 | NPC1 3108/4885RAB9A 4761/4885MMP13 4362/4885 |
| US-20040082774-A1 | Novel phosphate and thiophosphate protecting groups | TYMP, MTAP, PPIP5K2 | NPC1 3884/4885RAB9A 4334/4885MMP13 3426/4885 |
| US-20160184285-A1 | PIPERIDINE UREA DERIVATIVES | PRMT1, TNKS, PRMT3 | NPC1 3643/4885RAB9A 2999/4885MMP13 2196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.